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Original Research
Analysis of Platelet-Rich Plasma Extraction
Variations in Platelet and Blood Components
Between 4 Common Commercial Kits
Jane Fitzpatrick,*†‡ FACSP, MBBS, Max K. Bulsara,§ PhD, MSc, BSc(Hons),
Paul Robert McCrory,|| PhD, FFSEM, FACSP, FRACP, MBBS,
Martin D. Richardson,{ FRACS, MBBS, MS, and Ming Hao Zheng,‡# PhD, DM, FRCPath, FRCPA
Investigation performed at the University of Western Australia,
Crawley, Western Australia, Australia
Background: Platelet-rich plasma (PRP) has been extensively used as a treatment in tissue healing in tendinopathy, muscle injury,
and osteoarthritis. However, there is variation in methods of extraction, and this produces different types of PRP.
Purpose: To determine the composition of PRP obtained from 4 commercial separation kits, which would allow assessment of
current classification systems used in cross-study comparisons.
Study Design: Controlled laboratory study.
Methods: Three normal adults each donated 181 mL of whole blood, some of which served as a control and the remainder of
which was processed through 4 PRP separation kits: GPS III (Biomet Biologics), Smart-Prep2 (Harvest Terumo), Magellan
(Arteriocyte Medical Systems), and ACP (Device Technologies). The resultant PRP was tested for platelet count, red blood cell
count, and white blood cell count, including differential in a commercial pathology laboratory. Glucose and pHmeasurements were
obtained from a blood gas autoanalyzer machine.
Results: Three kits taking samples from the “buffy coat layer” were found to have greater concentrations of platelets (3-6 times
baseline), while 1 kit taking samples from plasma was found to have platelet concentrations of only 1.5 times baseline. The same 3
kits produced an increased concentration of white blood cells (3-6 times baseline); these consisted of neutrophils, leukocytes, and
monocytes. This represents high concentrations of platelets and white blood cells. A small drop in pH was thought to relate to the
citrate used in the sample preparation. Interestingly, an unexpected increase in glucose concentrations, with 3 to 6 times greater
than baseline levels, was found in all samples.
Conclusion: This study reveals the variation of blood components, including platelets, red blood cells, leukocytes, pH, and glu-
cose in PRP extractions. The high concentrations of cells are important, as the white blood cell count in PRP samples has fre-
quently been ignored, being considered insignificant. The lack of standardization of PRP preparation for clinical use has
contributed at least in part to the varying clinical efficacy in PRP use.
Clinical Relevance: The variation of platelet and other blood component concentrations between commercial PRP kits may affect
clinical treatment outcomes. There is a need for standardization of PRP for clinical use.
Keywords: platelet-rich plasma; PRP; leukocyte; osteoarthritis; tendinopathy
Platelet-rich plasma (PRP) is defined as a platelet-rich
concentrate with higher-than-baseline levels of platelets
when compared with whole blood. PRP is increasingly used
in prospective clinical studies to improve tissue healing,
particularly with regard to tendinitis.5,7,13,21,22,30,33,36 A
small number of randomized controlled trials have shown
the positive benefit of PRP in tendinopathy.13,22,25,33 It has
been hypothesized that this is due to platelet-derived
growth factor (PDGF), transforming growth factor beta
(TGF-b), vascular endothelial growth factor (VEGF),
insulin-like growth factor 1 (IGF-1), and hepatocyte growth
factor (HGF), which are released from the alpha granules
during in vivo activation of platelets3,5,6,9,10,12,26,41 or sub-
sequently produced by the cellular matrix of the tendon.
DeLong et al14 considered that PRP preparations can be
divided into 2 forms: 1 plasma based, the other based on
buffy coat preparations. Plasma-based preparations aim to
capture platelets from the plasma after centrifugation and
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exclude red and white blood cells. Generally these kits pro-
duce smaller increases in platelets than the kits that take
platelets from both the plasma and the more cellular ‘‘buffy
coat.’’8,9,18
There has been some discussion about whether the effi-
cacy of the PRP is affected by the inclusion of the white
blood cells.2,27 Moojen et al31 considered that there may
be positive effects from the white blood cells acting as anti-
microbial agents. Other authors have suggested that the
platelets themselves may already have this property.38
There may also be negative effects from these white blood
cells in causing further inflammation, leading to fibrosis, or
from the release of catabolic cytokines.2,32 This effect may
be more prevalent with neutrophils than other white blood
cells.2 Recent meta-analyses of PRP in tendinopathy iden-
tified that leukocyte-rich PRP had a strongly positive out-
come in the treatment of tendinopathies.19,34
There has also been discussion about whether the pH of
the resultant PRP will affect platelet function,39 and thus
whether the PRP produced should be ‘‘buffered.’’
Because it is likely to be important in the management of
different conditions to have certain types of PRP used,15 all
commercial kits should be validated for cell and PRP type,
but this has not always been the case. The purpose of this
study was to validate all kits available in Australia for their
composition of platelet, red and white blood cell counts, pH,
and glucose levels using a single-donor model. A recommen-
dation could then be made as to which PRP kits/types are
associated with the best results in the treatment of differ-
ent musculoskeletal conditions such as tendinopathy and
osteoarthritis.
METHODS
Three healthy adult human subjects were recruited and con-
sented for this trial (2women, 1man; age range, 25-35 years).
Description of Common Commercial Kits
A review of all kits was undertaken as shown in Table 1
based on the International Olympic Committee (IOC) con-
sensus paper on the use of PRP in sports medicine.16 It was
decided that only kits producing PRP, autologous condi-
tioned plasma, or pure platelets would be assessed. Only
kits producing PRP from whole blood for use in musculo-
skeletal conditions such as tendinitis, muscle injuries, or
osteoarthritis were selected. Kits were excluded if they pro-
duced platelet-rich fibrin or bone marrow samples. Thus, 8
potential kits were available for testing.
Cell saver–based pure platelet systems requiring a min-
imum sample of 200 mL of whole blood for processing24
were not deemed appropriate to study, as this large sample
was regarded as impractical for office use. The Caption
pure platelet kit was not commercially available at the time
of testing, and therefore, 6 potential kits were available for
TABLE 1
Commercially Available Kits for the Production of Platelet Productsa
Device Name Company Name of Product Comments
GPS III Biomet Platelet-rich plasma Tested
SmartPrep2 Harvest Platelet-rich plasma Tested
Magellan Arteriocyte Medical Platelet-rich plasma Tested
Angel Sorin Platelet-rich plasma Not available for testing
CS Genesis Platelet-rich plasma Not available for testing
ACP Arthrex Autologous conditioned plasma Tested
PRFM Fibrinet System Cascade Platelet-rich fibrin Not tested, fibrin membrane
PRF and Vivostat Choukroun’s Platelet-rich fibrin Not tested, fibrin membrane
BMAC DePuy Platelet-rich plasma and stem cells Not tested, bone marrow
Cell saver–based systems Electa,
Haemonetics, CATS, BRAT
Several Pure platelets Not tested, volume required >200 mL
Caption Not yet marketed Pure platelets Not tested, not available
Total 12 companies 4 tested
aTable derived from Engebretson et al.16
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study. Of these, only 4 were commercially available in Aus-
tralia at the time of testing: GPS III (Biomet Biologics),
SmartPrep2 (Terumo Harvest), Magellan (Arteriocyte
Medical Systems), and ACP (Device Technologies,
Arthrex). All companies agreed for their kits to be used in
the trial and provided the kits.
Sample Collection and Processing
All samples were collected from the subjects by the
senior author (J.F.) and were processed immediately. A
total of 181 mL of blood was drawn from each subject: 5
mL was used for the control sample, 52 mL for each
of the PRP-based kits (GPS III, SmartPrep2, and
Magellan), and 15 mL for the ACP kit. The samples
were processed according to the manufacturers’ instruc-
tions to produce 6 to 7 mL of finished product, as shown
in Table 2.
The samples were then processed: 1.5 mL from the PRP
samples and the control blood were put into a tube for anal-
ysis on a blood gas testing machine (ABL800 Flex; Radiom-
eter), generating results for pH, Kþ, Naþ, Cl–, glucose, and
lactate. The remaining control blood and PRP samples were
placed into a collection tube for analysis on a Coulter LH
250 automated analyzer (Beckman Coulter Inc) within
30 minutes of collection to measure full blood count and
white blood cell count with differential.
Classification of the PRP Produced
The results from the analysis were assessed based on the
PAW (platelet, activation, white blood cells)15 and the Mis-
hra sports medicine PRP classification29 systems. The PAW
system classifies PRP based on platelet numbers, the man-
ner in which activation occurs, and the presence or absence
of white blood cells. The Mishra sports medicine PRP clas-
sification system is based on platelet concentration, the
presence or absence of white blood cells, and whether the
PRP has been activated with exogenous thrombin or cal-
cium chloride.
Statistical Analysis
All statistical analyses were performed using STATA ver-
sion 13 (Stata Corp). All variables had a calculated mean
and standard deviation. Each subject was used as their own
control, and thus, change from mean was relative to their
own control result.
RESULTS
Comparison of Cellular Components
We first compared the cellular components of platelets, leu-
kocytes, and red blood cells between these 4 kits using
TABLE 2
Preparation of PRP Samplesa
System Blood Volume, mL Anticoagulant Volume, mL Centrifugal Force, g-force Centrifuge Time, min Volume Produced, mL
GPS III 52 ACD-A 8 1100 15 6-7
SmartPrep2 52 ACD-A 8 1250/1050 14 6-7
Magellan 52 ACD-A 8 1200 17 6-7
ACP 15 ACD-A 2 1500 5 6-7
aACD-A, anticoagulant citrate dextrose solution A; PRP, platelet-rich plasma.
TABLE 3
Cellular Dataa
Kit Cell Type Mean, 109/L SD, 109/L Median, 109/L Min, 109/L Max, 109/L
Control Platelets 269 106 290 154 362
WBC 8.73 3.75 8.9 4.9 12.4
RBC 4.7 0.436 4.5 4.4 5.2
ACP Platelets 412 140 424 266 546
WBC 1.3 0.781 7.7 0.4 1.8
RBC 0.0333 0.0577 0 0 0.1
GPS Platelets 964 551 760 544 1588
WBC 35.8 10.8 41.8 23.3 42.3
RBC 1.03 0.289 1.2 0.7 1.2
SmartPrep Platelets 1224 560 1262 646 1764
WBC 24.7 8.69 26.1 15.4 32.6
RBC 1.43 0.306 1.5 1.1 1.7
Magellan Platelets 1266 831 1153 497 2148
WBC 31.4 9.4 35.2 20.7 38.3
RBC 1.03 0.153 1.0 0.9 1.2
aRBC, red blood cell count; WBC, total white blood cell count.
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standard methods on 3 human subjects. A summary of data
is presented in Table 3. The values for total platelet count
as well as red and white blood cell counts are presented
compared with controls.
Platelets. An increase in platelet production was dem-
onstrated compared with baseline in all kits (Figure 1).
The ACP kit produced a 1 to 1.7 times baseline level of
platelets (412  109/L), which is consistent with the liter-
ature for this kit and open-tube single- or double-spin sys-
tems.4,8,37,41TheMagellan (1266 109/L),GPS (964 109/L),
and SmartPrep (1224  109/L) kits produce 3 and 6 times
baseline platelet concentrations, consistent with previous
data.8,9,17,18,23,24
Red Blood Cells. All kits significantly reduced red blood
cell counts compared with controls, as seen in Figure 2. The
ACP kit virtually eliminated red blood cells. The GPS,
SmartPrep, and Magellan kits reduced the red blood cells
by 3 to 6 times baseline levels.
White Blood Cells.White blood cell counts are of great
importance. Compared with controls (white blood cell
count, 8.73  109/L), the only kit to reduce the white
blood cell count was the plasma system (ACP) (1.3 
109/L), which reduced the white blood cell count by 5 to
22 times, almost eliminating the white blood cells. The
GPS III (35.8  109/L), SmartPrep2 (24.7  109/L), and
Magellan (31.4  109/L) kits actively concentrated white
blood cells 3 to 5 times baseline levels (Figure 3). This is
consistent with the results found by Carmona et al.7
Similar increases across all 3 kits were demonstrated.
Our results showed much higher levels of white blood
cell concentration than have been indicated by others.7,8
When the white blood cell count is broken into a differ-
ential white blood cell count, the majority of cells are neu-
trophils and lymphocytes (Table 4 and Figure 4). Compared
with controls (5.5  109/L), the GPS and Magellan kits
contained greater mean neutrophil counts (15.4 and 15.1
 109/L, respectively). The SmartPrep kit had a lower mean
neutrophil count (6.47  109/L), and the ACP kit had a
negligible mean neutrophil count (0.4  109/L). Compared
with controls (2.37 109/L), the mean lymphocyte counts of
the GPS (15.9  109/L), SmartPrep (14.0  109/L), and
Magellan (12.5 109/L) were higher but similar across kits.
The ACP kit had negligible lymphocytes (0.7  109/L). The
increase in total white blood cell count was similar across
the 3 buffy coat layer kits (GPS, SmartPrep, andMagellan).
However, the relative increase in neutrophils was much
greater for the GPS and the Magellan kits.
Comparison of Chemical Composition
PRP from the kits was assessed for glucose and pH using
the Radiometer ABL800 Flex. The data for pH and glucose
are shown in Table 5 and Figures 5 and 6.
Compared with the glucose control of 4.2 mmol/L, all
PRP produced contained a high level of glucose ranging
from 15.8 to 23.6 mmol/L. This reflects an increase in
glucose of 4 to 6 times baseline.
The mean pH of the controls was 7.1. The mean pH of the
PRP produced ranged from 6.59 (SmartPrep) to 7.05 (GPS).
The lower pH in the kit samples is related to the use of the
anticoagulant citrate dextrose solution–formula A (ACD-A)
anticoagulant. The amount of ACD-A used was the same
ratio for all kits by volume.
Figure 1. Platelet counts by kit type. Figure 2. Red blood cell counts by kit type.
Figure 3. Total white blood cell counts by kit type.
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DISCUSSION
There are various kits available for the separation of PRP
in clinical practice. As a specific ‘‘dose’’ of platelets may be
required to achieve a clinical effect, it is important to iden-
tify the kits that produce different doses.15 Using a single-
donor protocol, we have analyzed the blood components of 4
of the most common commercial kits available to medical
practitioners in Australia. We have shown an increase in
platelets from baseline in all the kits with large variations.
This was found to be 1 to 1.5 for plasma-type kits (ACP) and
between 3 and 6 times for buffy coat layer kits (GPS III,
Magellan, SmartPrep2). This confirms the work of Castillo
et al,9 who similarly compared 3 kits (Magellan, Cascade,
and GPS). In addition, there is variation in the numbers of
neutrophils, leukocytes, and monocytes between the kits.
The plasma system (ACP) reduced the white blood cell
count by 5 to 22 times, almost eliminating the white blood
cells. The buffy coat kits (GPS III, SmartPrep2, and Magel-
lan) actively concentrated white blood cells 3 to 5 times
baseline. The increase in total white blood cell count was
similar across the 3 buffy coat layer kits (GPS, SmartPrep,
and Magellan). However, the relative increase in neutro-
phils was much greater for the GPS and Magellan kits.
A small reduction in pH was thought to relate to the
citrate used in the sample preparation. This reduction is
not thought to be of clinical significance. Based on the small
drop in pH, it does not seem necessary to buffer the PRP
unless this change in pH can be shown to negatively impact
the production of growth factors.
No studies have reported the level of glucose in PRP
produced previously. One of the surprising findings in this
study was the significant increases in glucose concentra-
tion of 4 to 6 times baseline in all kits. This has not been
previously reported as a significant variable, and the clin-
ical significance of this factor is unknown. It is of interest
that glucose solutions at concentrations between 12% and
20% have been used in prolotherapy injections with
TABLE 4
White Blood Cell Differential Countsa
Kit Mean ± SD, 109/L Median (Range), 109/L
Control
WBC 8.73 ± 3.75 8.9 (4.9-12.4)
Neutrophils 5.5 ± 2.91 5.3 (2.7-8.5)
Lymphocytes 2.37 ± 0.85 2.4 (1.5-3.2)
Monocytes 0.6 ± 0.173 0.5 (0.5-0.8)
ACP
WBC 1.3 ± 0.781 1.7 (0.4-1.8)
Neutrophils 0.4 ± 0.265 0.5 (0.1-0.6)
Lymphocytes 0.7 ± 0.436 0.9 (0.2-1.0)
Monocytes 0.167 ± 0.115 0.1 (0.1-0.3)
GPS
WBC 35.8 ± 10.8 41.8 (23.3-42.3)
Neutrophils 15.4 ± 5.05 14 (11.2-21)
Lymphocytes 15.9 ± 7.73 14.6 (8.9-24.2)
Monocytes 3.8 ± 1.1 3.8 (2.7-4.9)
Smart Prep
WBC 24.7 ± 8.69 26.1 (15.4-32.6)
Neutrophils 6.47 ± 1.86 7 (4.4-8)
Lymphocytes 14 ± 6.36 13 (8.2-20.8)
Monocytes 3.57 ± 1 3.5 (2.6-4.6)
Magellan
WBC 31.4 ± 9.4 35.2 (20.7-38.3)
Neutrophils 15.1 ± 3.93 16.6 (10.6-18)
Lymphocytes 12.5 ± 5.72 12 (7.1-18.5)
Monocytes 3.27 ± 1.03 3 (2.4-4.4)
aWBC, total white blood cell count.
Figure 4. Neutrophil and lymphocyte counts by kit type.
TABLE 5
pH and Glucose Data
Kit Mean ± SD, mmol/L Median (Range), mmol/L
Control
pH 7.1 ± 0.28 7.12 (7.07-7.12)
Glucose 4.2 ± 0.529 4.4 (3.6-4.6)
ACP
pH 6.87 ± 0.256 6.99 (6.57-7.04)
Glucose 18.5 ± 2.73 17.7 (16.2-21.5)
GPS
pH 7.05 ± 0.02 7.05 (7.03-7.07)
Glucose 15.8 ± 1.07 15.2 (15.1-17.0)
Smart Prep
pH 6.59 ± 0.329 6.61 (6.55-6.61)
Glucose 23.6 ± 1.36 23.8 (22.2-24.9)
Magellan
pH 6.66 ± 0.102 6.69 (6.54-6.74)
Glucose 22.3 ± 0.907 22.7 (21.3-23.0)
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varying results.1,11,20 It is likely this is derived from the
use of the ACD-A and is thus related to the preparation
technique consistent to all kits. If one takes 5 mL of a 10%
glucose solution (2.8-mmol solution) for injection, this
would contain 0.5 g of glucose. If we take 5 mL of PRP
produced in any of the studied kits at 20 mmol/L (70%
glucose solution), this would give us 3 g of glucose. In
simple terms, our PRP samples are producing a 6-times
glucose concentration compared with glucose solutions
used in prolotherapy. This may be important as part of the
factors producing a clinical response.
Essentially there are 2 main types of PRP preparation
methods. After centrifugation, there are 3 key layers, as
shown in Figure 7. Plasma-based systems take product
from the yellow relatively acellular plasma layer. These
systems aim to exclude red and white blood cells from the
preparation and to collect as many platelets from the
remaining ‘‘plasma’’ layer as possible. As many of the plate-
lets are in the buffy coat layer, the resultant product is low
in red and white blood cells and has only a 1.5 to 1.7 times
baseline level of platelets. This is well demonstrated by the
results from the ACP kit in our study. The second type of
PRP product is made from the buffy coat floating above the
red blood cell layer. Levels of platelets at 3 to 6 times base-
line levels are expected as the product is coming from a
more platelet-dense environment.6,9 Again, this is confirmed
by our testing, with the GPS III, Magellan, and SmartPrep2
kits having much higher platelet concentrations.
In producing PRP, all kits aim to reduce the red blood cell
count6,9,12 and increase the collection of platelets. Some
white blood cells are captured at the same time.6,9 Due to
the addition of citrate to the blood being collected, there is
likely to be a drop in pH of the sample produced. This is the
first paper to identify how other variables like lactate or
glucose are changed by this process. Generally, in most
literature review papers, the white blood cell count is
ignored or regarded as negligible. We feel that these aspects
of PRP systems should be more highly noted in future lit-
erature reports as the concentration of white blood cells is
as great as that of the platelets and there is glucose present
in the end product.
Studies by others have also shown variation of platelet
levels, growth factor and cytokine levels,32 and total white
blood cell counts across PRP preparation meth-
ods.8,9,17,18,24,27,37,40,41 However, the most important find-
ing in our study is that the white blood cell counts are
significantly more concentrated than previously thought.
The ACP kit was the only one in our series that reduced
the white blood cell count by a factor of about 9. This may be
an important point of difference if the white blood cells are
not beneficial. The other 3 kits (GPS III, Magellan, Smart-
Prep2) concentrated the white blood cell count by 3 to 5
times, a similar increase to platelet concentration. Thus,
these white blood cells are not contaminants as their levels
are as high as the primary ingredient: platelets. Their
levels may be regarded as potentially clinically significant.
Furthermore, we assessed the white blood cell differential
count and found that the cellular concentration of white
blood cells was up to 40% neutrophils and lymphocytes each
and a further 10%made up of monocytes. The remainder of
the cells were basophils and eosinophils in small quantities.
An increase in the growth factor VEGF would be expected
as the number of lymphocytes increases. These lympho-
cytes may play an important role in further enhancing the
tissue repair processes, but they may also lead to increased
local inflammation.
Figure 5. pH by kit type.
Figure 6. Glucose by kit type.
Figure 7. Platelet-rich plasma in GPS kit after centrifugation.
6 Fitzpatrick et al The Orthopaedic Journal of Sports Medicine
White blood cells may contribute to the modulation of
inflammatory and platelet activation, thereby acting to
potentiate the tissue repair mechanism. It is possible that
the white blood cells may confer an advantage to the
patient in reducing the chance of infection or modulating
the inflammatory response.31,35 This may be an important
consideration in those clinical settings where the patient is
at greater risk, such as with intra-articular procedures or at
the time of surgery. Furthermore, Zimmermann et al41
found that the increased white blood cell count was respon-
sible for between one-third and one-half of the variation on
growth factors found in their samples. They found a positive
correlation between the white blood cell count and VEGF
(known to come from the white blood cells) and PDGF.
On the other hand, others have shown that white blood
cells appear to have a deleterious effect on the tissue,27
resulting in increased inflammation and further scarring.
These negative effects are largely due to neutrophils and
include the release of oxygen-free radicals, catabolic cyto-
kines, matrix metalloproteinases (MMPs), and interleukin
B, which degrade tissue.14
A recent meta-analysis of the effectiveness of PRP in
tendinopathy has shown that leukocyte-rich PRP (LR-PRP)
is the most effective in the treatment of tendinopathy.19
This study allows us to recommend PRP produced by the
GPS III, SmartPrep2, andMagellan kits in the treatment of
tendinopathy. By contrast, 2 recent reviews of the effective-
ness of PRP in osteoarthritis have shown that leukocyte-
poor PRP (LP-PRP) may be more effective.28,34
One of the surprising new findings in this study was the
significant increases in glucose concentration of 4 to 6 times
baseline in all kits. This has not been previously reported as
a significant variable, and the clinical significance of this
factor is unknown. It is of interest that glucose solutions at
concentrations of between 12% and 20% have been used in
prolotherapy injections with varying results.1,11,20 The clin-
ical significance of this remains uncertain. This was
thought to be important as prolotherapy with glucose has
been used in the treatment of musculoskeletal injuries.
Kit validation studies help to classify kits into those
deemed similar enough to allow results from papers using
kits to be compared. Some kit classification systems have
been proposed in the past.15,29 Table 6 shows the PRP kits
classified according to both the PAW and Mishra classifica-
tion systems. The classification proposed by Mishra et al29
allows for platelet concentrations >5 or <5 times baseline.
We found 3 to 6 times baseline values in the buffy coat kits
and 1.5 in the plasma kits. This classification system with a
cutoff of ±5 times concentration does not fit for either buffy
coat or plasma system results from our study. The white
blood cells are recorded only as present or absent, and there
is no accounting for the level of white blood cells. The PAW
classification system proposed by DeLong et al15 is appro-
priate for the classification of platelets, classifying our
tested kits into 3 different groups, but it simply classifies
the white blood cells as absent or present. Given the high
concentration of white blood cells found in our laboratory
analysis, this classification system does not adequately
account for the high numbers of white blood cells, including
both neutrophils and lymphocytes found in the PRP pre-
parations studied. If these cells are found to be significant
for efficacy, a further breakdown of types of PRP to ade-
quately include white blood cells will be needed. Kits clas-
sified in the same class would then be able to have their
results compared as a group when meta-analysis or com-
parison studies are being undertaken.
CONCLUSION
This study identifies the large variations in composition and
concentration of platelets, white blood cell counts, and the
differential count of neutrophils and lymphocytes as well as
the presence of high levels of glucose between 4 commercial
PRP kits. The clinical significance of this is that these varia-
tions must be taken into account when assessing the results
of clinical trials and in the choice of preparation by practi-
tioners. This study highlights the need for standardization of
platelet-rich plasma extraction for clinical use.
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TABLE 6
PRP kits by PAW and Mishra (Sports Medicine) Classificationsa
PAW Classification Mishra Classification
Kit Platelets WBC Neutrophils Resultb Activation (PAW/Mishra) WBC Platelets Resultc
ACP P2 B b P2Bb N/A Minimal <5 3B
Magellan P4 A a P4Aa N/A Increased <5 1B
GPS III P3 A a P3Aa N/A Increased <5 1B
SmartPrep2 P3 A a P3Aa N/A Increased <5 1B
aN/A, not applicable; WBC, total white blood cell count.
bPAW classification: platelet counts: P2 ¼ baseline to 750,000; P3 ¼ 750,000-1,250,000; P4 ¼ >1,250,000. Total WCC: A ¼ above baseline,
B ¼ below or equal to baseline. Neutrophil count: a ¼ above baseline, b ¼ below baseline.
cMishra classification: type 1B ¼ increased WCC, no activation, platelet count <5 times baseline; type 3B ¼minimal WCC, no activation,
platelet count <5 times baseline.
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Melbourne, Australia, for the provision of the Radiome-
ter ABL800 Flex for the pH and glucose readings, in
addition to Suzie Moreton, Epworth librarian, for her
ongoing support.
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